vs
爱玛客（ARMK）与吉利德科学（GILD）财务数据对比。点击上方公司名可切换其他公司
吉利德科学的季度营收约是爱玛客的1.6倍（$7.9B vs $4.8B），吉利德科学净利率更高（27.5% vs 2.0%，领先25.6%），爱玛客同比增速更快（6.1% vs 4.7%），吉利德科学自由现金流更多（$3.1B vs $-904.4M），过去两年吉利德科学的营收复合增速更高（8.9% vs 7.3%）
爱玛客是美国知名的餐饮服务与设施管理服务商，服务覆盖教育、司法监管、医疗、企业、休闲文旅等多个领域，业务遍布北美地区及英国、德国、智利、爱尔兰、西班牙在内的14个国家，为各场景客户提供专业后勤支持解决方案。
吉利德科学是总部位于美国加利福尼亚州福斯特城的生物制药企业，专注于研发抗病毒药物，覆盖艾滋病、乙型肝炎、丙型肝炎、流感、新冠等治疗领域，核心产品包括来迪派韦索磷布韦、索磷布韦等，现为纳斯达克100指数及标普100指数成分股。
ARMK vs GILD — 直观对比
营收规模更大
GILD
是对方的1.6倍
$4.8B
营收增速更快
ARMK
高出1.4%
4.7%
净利率更高
GILD
高出25.6%
2.0%
自由现金流更多
GILD
多$4.0B
$-904.4M
两年增速更快
GILD
近两年复合增速
7.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $4.8B | $7.9B |
| 净利润 | $96.2M | $2.2B |
| 毛利率 | — | 79.5% |
| 营业利润率 | 4.5% | 25.0% |
| 净利率 | 2.0% | 27.5% |
| 营收同比 | 6.1% | 4.7% |
| 净利润同比 | -9.0% | 22.4% |
| 每股收益（稀释后） | $0.36 | $1.75 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ARMKGILD
| Q1 26 | $4.8B | — | ||
| Q4 25 | $5.0B | $7.9B | ||
| Q3 25 | — | $7.8B | ||
| Q2 25 | $4.6B | $7.1B | ||
| Q1 25 | $4.3B | $6.7B | ||
| Q4 24 | $4.6B | $7.6B | ||
| Q3 24 | $4.4B | $7.5B | ||
| Q2 24 | $4.4B | $7.0B |
净利润ARMKGILD
| Q1 26 | $96.2M | — | ||
| Q4 25 | $87.1M | $2.2B | ||
| Q3 25 | — | $3.1B | ||
| Q2 25 | $71.8M | $2.0B | ||
| Q1 25 | $61.9M | $1.3B | ||
| Q4 24 | $105.6M | $1.8B | ||
| Q3 24 | $122.4M | $1.3B | ||
| Q2 24 | $58.1M | $1.6B |
毛利率ARMKGILD
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 79.8% | ||
| Q2 25 | — | 78.8% | ||
| Q1 25 | — | 76.9% | ||
| Q4 24 | — | 79.1% | ||
| Q3 24 | — | 79.1% | ||
| Q2 24 | — | 77.8% |
营业利润率ARMKGILD
| Q1 26 | 4.5% | — | ||
| Q4 25 | 4.3% | 25.0% | ||
| Q3 25 | — | 42.8% | ||
| Q2 25 | 3.9% | 34.9% | ||
| Q1 25 | 4.1% | 33.6% | ||
| Q4 24 | 4.8% | 32.4% | ||
| Q3 24 | 5.0% | 11.8% | ||
| Q2 24 | 3.7% | 38.0% |
净利率ARMKGILD
| Q1 26 | 2.0% | — | ||
| Q4 25 | 1.7% | 27.5% | ||
| Q3 25 | — | 39.3% | ||
| Q2 25 | 1.6% | 27.7% | ||
| Q1 25 | 1.4% | 19.7% | ||
| Q4 24 | 2.3% | 23.6% | ||
| Q3 24 | 2.8% | 16.6% | ||
| Q2 24 | 1.3% | 23.2% |
每股收益（稀释后）ARMKGILD
| Q1 26 | $0.36 | — | ||
| Q4 25 | $0.33 | $1.75 | ||
| Q3 25 | — | $2.43 | ||
| Q2 25 | $0.27 | $1.56 | ||
| Q1 25 | $0.23 | $1.04 | ||
| Q4 24 | $0.39 | $1.43 | ||
| Q3 24 | $0.46 | $1.00 | ||
| Q2 24 | $0.22 | $1.29 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $439.6M | $68.0M |
| 总债务越低越好 | $6.2B | $24.9B |
| 股东权益账面价值 | $3.2B | $22.7B |
| 总资产 | $13.5B | $59.0B |
| 负债/权益比越低杠杆越低 | 1.94× | 1.10× |
8季度趋势，按日历期对齐
现金及短期投资ARMKGILD
| Q1 26 | $439.6M | — | ||
| Q4 25 | $639.1M | $68.0M | ||
| Q3 25 | — | $19.0M | ||
| Q2 25 | $501.5M | $69.0M | ||
| Q1 25 | $920.5M | — | ||
| Q4 24 | $484.1M | — | ||
| Q3 24 | $672.5M | — | ||
| Q2 24 | $436.1M | — |
总债务ARMKGILD
| Q1 26 | $6.2B | — | ||
| Q4 25 | $5.4B | $24.9B | ||
| Q3 25 | — | $24.9B | ||
| Q2 25 | $6.3B | $24.9B | ||
| Q1 25 | $6.1B | $25.0B | ||
| Q4 24 | $5.0B | $26.7B | ||
| Q3 24 | $4.3B | $23.2B | ||
| Q2 24 | $5.0B | $23.3B |
股东权益ARMKGILD
| Q1 26 | $3.2B | — | ||
| Q4 25 | $3.1B | $22.7B | ||
| Q3 25 | — | $21.5B | ||
| Q2 25 | $3.1B | $19.7B | ||
| Q1 25 | $3.0B | $19.2B | ||
| Q4 24 | $3.1B | $19.3B | ||
| Q3 24 | $3.0B | $18.5B | ||
| Q2 24 | $2.9B | $18.3B |
总资产ARMKGILD
| Q1 26 | $13.5B | — | ||
| Q4 25 | $13.3B | $59.0B | ||
| Q3 25 | — | $58.5B | ||
| Q2 25 | $13.3B | $55.7B | ||
| Q1 25 | $13.5B | $56.4B | ||
| Q4 24 | $12.7B | $59.0B | ||
| Q3 24 | $12.7B | $54.5B | ||
| Q2 24 | $12.5B | $53.6B |
负债/权益比ARMKGILD
| Q1 26 | 1.94× | — | ||
| Q4 25 | 1.71× | 1.10× | ||
| Q3 25 | — | 1.16× | ||
| Q2 25 | 2.03× | 1.27× | ||
| Q1 25 | 2.02× | 1.30× | ||
| Q4 24 | 1.61× | 1.38× | ||
| Q3 24 | 1.42× | 1.26× | ||
| Q2 24 | 1.71× | 1.28× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-782.2M | $3.3B |
| 自由现金流经营现金流 - 资本支出 | $-904.4M | $3.1B |
| 自由现金流率自由现金流/营收 | -18.7% | 39.4% |
| 资本支出强度资本支出/营收 | 2.5% | 2.6% |
| 现金转化率经营现金流/净利润 | -8.13× | 1.52× |
| 过去12个月自由现金流最近4个季度 | — | $9.5B |
8季度趋势，按日历期对齐
经营现金流ARMKGILD
| Q1 26 | $-782.2M | — | ||
| Q4 25 | — | $3.3B | ||
| Q3 25 | — | $4.1B | ||
| Q2 25 | $76.7M | $827.0M | ||
| Q1 25 | $255.9M | $1.8B | ||
| Q4 24 | $-587.2M | $3.0B | ||
| Q3 24 | $1.0B | $4.3B | ||
| Q2 24 | $140.7M | $1.3B |
自由现金流ARMKGILD
| Q1 26 | $-904.4M | — | ||
| Q4 25 | — | $3.1B | ||
| Q3 25 | — | $4.0B | ||
| Q2 25 | $-34.7M | $720.0M | ||
| Q1 25 | $140.1M | $1.7B | ||
| Q4 24 | $-707.0M | $2.8B | ||
| Q3 24 | $882.3M | $4.2B | ||
| Q2 24 | $55.6M | $1.2B |
自由现金流率ARMKGILD
| Q1 26 | -18.7% | — | ||
| Q4 25 | — | 39.4% | ||
| Q3 25 | — | 51.0% | ||
| Q2 25 | -0.8% | 10.2% | ||
| Q1 25 | 3.3% | 24.8% | ||
| Q4 24 | -15.5% | 37.4% | ||
| Q3 24 | 20.0% | 55.2% | ||
| Q2 24 | 1.3% | 17.2% |
资本支出强度ARMKGILD
| Q1 26 | 2.5% | — | ||
| Q4 25 | 2.8% | 2.6% | ||
| Q3 25 | — | 1.9% | ||
| Q2 25 | 2.4% | 1.5% | ||
| Q1 25 | 2.7% | 1.6% | ||
| Q4 24 | 2.6% | 1.9% | ||
| Q3 24 | 3.2% | 1.9% | ||
| Q2 24 | 1.9% | 1.9% |
现金转化率ARMKGILD
| Q1 26 | -8.13× | — | ||
| Q4 25 | — | 1.52× | ||
| Q3 25 | — | 1.35× | ||
| Q2 25 | 1.07× | 0.42× | ||
| Q1 25 | 4.14× | 1.34× | ||
| Q4 24 | -5.56× | 1.67× | ||
| Q3 24 | 8.35× | 3.44× | ||
| Q2 24 | 2.42× | 0.82× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ARMK
| Education | $1.1B | 22% |
| Sports Leisure Corrections | $961.2M | 20% |
| Food And Support Services International | $847.8M | 18% |
| Other | $621.6M | 13% |
| Businessand Industry | $510.6M | 11% |
| Health Care | $421.3M | 9% |
| Facility Services | $382.9M | 8% |
GILD
| Other | $3.4B | 43% |
| HIV Products Biktarvy | $3.3B | 41% |
| HIV Products Odefsey | $239.0M | 3% |
| Liver Disease Products Other Liver Disease | $170.0M | 2% |
| HIV Products Other HIV | $155.0M | 2% |
| Other Products Yescarta | $150.0M | 2% |
| Liver Disease Products Vemlidy | $149.0M | 2% |
| Liver Disease Products Sofosbuvir Velpatasvir | $140.0M | 2% |
| HIV Products Symtuza Revenue Share | $98.0M | 1% |
| Veklury | $80.0M | 1% |
| Cell Therapy Products Tecartus | $32.0M | 0% |
| Royalty Contract And Other | $22.0M | 0% |
